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Sphingosine 1-phosphate (S1P) is an immune modulatory lipid mediator and has been
implicated in numerous pathophysiological processes. S1P is produced by sphingosine
kinase 1 (Sphk1) and Sphk2. Dendritic cells (DCs) are central for the direction of
immune responses and crucially involved in autoimmunity and cancerogenesis. In this
study we examined the function and survival of bone marrow-derived DCs under
long-term inflammatory stimulation. We observed that differentiated cells undergo
activation-induced cell death (AICD) upon LPS stimulation with an increased metabolic
activity shortly after stimulation, followed by a rapid activation of caspase 3 and
subsequent augmented apoptosis. Importantly, we highlight a profound role of Sphk1
in secretion of inflammatory cytokines and survival of dendritic cells that might be
mediated by a change in sphingolipid levels as well as by a change in STAT3 expression.
Cell growth during differentiation of Sphk1-deficient cells treated with the functional
S1P receptor antagonist FTYP was reduced. Importantly, in dendritic cells we did not
observe a compensatory regulation of Sphk2 mRNA in Sphk1-deficient cells. Instead,
we discovered a massive increase in Sphk1 mRNA concentration upon long-term
stimulation with LPS in wild type cells that might function as an attempt to rescue
from inflammation-caused cell death. Taken together, in this investigation we describe
details of a crucial involvement of sphingolipids and Sphk1 in AICD during long-term
immunogenic activity of DCs that might play an important role in autoimmunity and
might explain the differences in immune response observed in in vivo studies of Sphk1
modulation.
Keywords: sphingosine-1-phosphate, S1P, activation-induced-cell-death, dendritic cells, sphingosine kinase 1,
sphingosine kinase 2, FTY720P, Fingolimod
INTRODUCTION
Sphingosine 1-phosphate (S1P) is a pleiotropic lipidmediator and has been implicated in numerous
physiological processes and diseases that affect several organs in humans (Maceyka et al., 2011). S1P
is generated from sphingosine by phosphorylation via sphingosine kinase 1 and 2 (Sphk1 and 2;
Alemany et al., 2007; Spiegel and Milstien, 2007) and has a broad range of cellular functions which
include cell growth, survival, and differentiation as well as lymphocyte trafficking and inflammation
(Spiegel and Milstien, 2011; Arlt et al., 2014). S1P is also suspected to regulate cancerogenic
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conditions (Colie et al., 2009; Tabasinezhad et al., 2014; Zhang
et al., 2016). Interestingly, functions of S1P are depending on
its localization: Intracellular, it acts as a second messenger in
a variety of cell signaling processes, while upon secretion it
activates as an extracellular ligand five distinct G protein-coupled
receptors (S1PR1–S1PR5) in a paracrine or autocrine manner
(Van Brocklyn et al., 1998; Payne et al., 2002; Itagaki et al., 2007).
Because of its diverse and potent bioactivity, the concentrations
of S1P are tightly regulated by S1P-generating enzymes (Sphk1/2)
and several S1P metabolizing enzymes, namely S1P phosphatases
1 and 2, lipid phosphate phosphatases 1–3 (Le Stunff et al., 2002)
(Brindley and Pilquil, 2009) and S1P lyase which catalyzes an
irreversible cleavage of S1P (Bandhuvula and Saba, 2007; Saba
and de la Garza-Rodea, 2012).
S1P has been described in detail for its transactivating
properties in cell proliferation induced by PDGF (Olivera
and Spiegel, 1993), for the maintenance of islet viability (Lee
et al., 2013), for its inhibition of histone deacetylases HDAC1/2
(Hait et al., 2009) and for its intracellular effects on the
TRAF2/RIP1/NF-κB signaling pathway (Alvarez et al., 2010).We
have shown that S1P regulates cytokine secretion of immune
cells as it e.g., reduces IL-12p70 production shortly after
lipopolysaccharide (LPS)—triggered toll-like-receptor (TLR)-4
stimulation of splenocytes and dendritic cells (Schroeder et al.,
2011). Sphingosine 1-phosphate modulates antigen capture
(Japtok et al., 2012) and several selective S1P1 receptor-
modulating drugs are being investigated in clinical trials for
the treatment of diverse autoimmune disorders (Zu Heringdorf
et al., 2013). FTY720 (Fingolimod; Gilenya R©) is an immune-
modulatory prodrug which, after intracellular phosphorylation
(FTYP) by sphingosine kinase 2 and subsequent export,
mimics effects of the endogenous lipid mediator S1P via
S1P1, S1P3-5 receptors. Thus, Fingolimod has been introduced
to treat relapsing-remitting multiple sclerosis by inhibiting
central memory T cell egress from secondary lymphoid organs
(Brinkmann et al., 2010). However, Fingolimod has also direct
influences on immune cell function (Ottenlinger et al., 2016) and
is able to accumulate intracellularly (Schroder et al., 2015).
Dendritic cells (DCs) are key players of the immune system
as they play a central role in lymphocyte activation and
differentiation into T helper type 1 (Th1), Th2, Th17 as well
as cytotoxic T effector cells by the expression of co-stimulatory
molecules, chemokines, cytokines, and the presentation of MHC
molecules on their surface (Iwasaki and Medzhitov, 2004;
Siegemund et al., 2009; Arlt et al., 2014). With subtle differences
between conventional and plasmacytoid DCs, in general these
cells express all types of TLRs. TLR4 can be found on both,
the plasma membrane of the cell and at internal, endosomal
membranes (Gangloff, 2012). DCs are highly specialized for
antigen (cross-) presentation endowed with limited acidification
of their phagolysosomes to prevent complete proteolysis of
antigens. While being essential for immune defense, in the
presence of danger signals, such as an excess of apoptotic cells, the
host-derived nucleic acidsmay activate these TLRs and propagate
autoimmunity.
In order to understand the role of S1P metabolism
for dendritic cell activity and survival, in this study we
investigated S1P enzyme expression and sphingolipid
metabolism during TLR4-dependent activation of DCs.
Moreover, we analyzed cytokine production and dendritic
cell viability over time and unraveled a connection between
S1P metabolites, enzymes, and dendritic cell apoptosis
that might play a role in inflammatory responses and
autoimmunity.
MATERIALS AND METHODS
Isolation, Differentiation, and Stimulation
of Bone Marrow Cells
For isolation of bone marrow cells female WT C57BL/6
mice (Janvier, Saint Berthevin Cedex, France) and female
Sphk1-deficient (Sphk1−/−) mice [with C57BL/6 background,
generated by Genoway, Lyon, France as described by Pushparaj
et al. (2009)] bred at the local animal facility under specific
pathogen-free conditions were used. All animal experiments were
performed in accordance with the German animal welfare law
and had been declared to the Animal Welfare Officer as the
chairperson of the ethical oversight committee of the Goethe
University Frankfurt/Main. The animal housing facility was
licensed by the local authorities of the Regierungspraesidium
Darmstadt (Az: 32.62.1). The methods used to euthanize the
animals humanely were consistent with the recommendations
of the AVMA Guidelines for the Euthanasia of Animals. After
euthanasia of themice, tibia, and femur were dissected, washed in
ethanol and the ends of the bones were sliced. The bone marrow
was rinsed with PBS (Thermo Fisher Scientific, Darmstadt,
Germany) and erythrocytes were lysed by ACK buffer. Prior to
cultivation the bone marrow cells were washed with RPMI 1640
GlutaMax medium (Thermo Fisher Scientific) supplemented
with 10% FCS, 100 IU/ml penicillin, 100 µg/ml streptomycin,
10mM HEPES (Sigma–Aldrich, Steinheim, Germany), 1 mM
sodium pyruvate, and 50µM2-β-ME (Thermo Fisher Scientific).
The cells were seeded at a density of 0.5 × 106 cells/ml in
culture medium supplemented with 40 ng/ml GM-CSF and
cultured in a humidified incubator (5% CO2 and 37
◦C) for 7
days including one medium substitution. After this expansion
phase differentiated immature bone marrow derived DCs (BM-
DCs) were scraped and seeded at 1 × 106 cells/ml in 12- or
6-well plates with 1 or 2ml of culture medium without FCS and
GM-CSF. After 1 h of incubation at 5% CO2 and 37
◦C the cells
were stimulated with 1 µg/ml LPS from Escherichia coli O127:B8
(Sigma-Aldrich) and/or 1 µg/ml FTYP (kindly provided by V.
Brinkmann, Novartis, Basel, Switzerland), 10 µM staurosporine
(LC Laboratories, Woburn, Massachusetts), or left un-treated for
the indicated time points. In cell differentiation studies, FTYP
was applied daily to the cells within the expansion phase. After
stimulation, a part of the harvested cell suspension was used
for trypan blue (Sigma-Aldrich) staining. Upon centrifugation
the cell pellet was used either for RNA isolation, protein
extraction or lipid extraction. The supernatants were analyzed
by mouse-specific ELISAs for IL-23, IL-10, and IL-6 (R&D
Systems, Wiesbaden, Germany) according to the manufacturer’s
manual.
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Flow Cytometry
To identify apoptotic cells, BM-DCs were resuspended in
Annexin V binding buffer with Annexin V-FITC (ImmunoTools,
Friesoythe; Germany) for 15min in the dark. Hereafter, 7-AAD-
PercP (eBioscience, Frankfurt am Main, Germany) was given to
the cells (5min), which were finally suspended in 400µl Annexin
V binding buffer. Data were acquired with a FACSCantoII
flow cytometer (BD Biosciences, Heidelberg, Germany) and
analyzed using the software FlowJo (TreeStar, Ashland, OR).
Staurosporine treatment was used as a positive control.
Metabolic Activity
The XTT Cell Viability Assay (Thermo Fischer Scientific) was
used according to the manufacturer’s manual. In brief, the final
XTT solution was added to cell culture wells with cells or medium
only as a control. Upon 45min incubation time at 5% CO2 and
37◦C aliquots of the cells were analyzed in flat 96-well plates
(Greiner, Frickenhausen, Germany) at 460 and normalized to
650 nm.
Western Blotting
For Western blot analysis 5× 106 BM-DCs were stimulated with
1µg/ml LPS for the described time points. The pelleted cells were
lysed in a buffer containing 10mM HEPES-KOH, 10mM KCl,
0.1mM EDTA, 0.1mM EGTA, 0.5mMNaF, 1mMNa3VO4, and
1 × completeTM protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany) by sonification on ice for 10 s. Total
protein concentration was determined by BCA (Thermo Fisher
Scientific), according to manufacturer’s instructions. Whole cell
extracts were used for detection of Sphk1 (Abnova, Heidelberg,
Germany) and β-actin (Sigma-Aldrich). The cytosolic fraction
was used after pelleting the nuclear fraction by centrifugation
at 13,000 × g for 10min at 4◦C to detect caspase 3 (Cell
Signaling Technology, Danvers, MA) or β-actin (Sigma Aldrich).
According to the first antibodies, the second antibody anti-rabbit
IgG (GE Healthcare, Little Chalfont, UK) has been used. The
protein bands were detected by ECL (Thermo Fisher Scientific)
following the manufacturer’s protocol. Quantitative evaluation
was performed by densitometry using Quantity one (Bio-Rad,
Hercules, CA).
Lipid Extraction and Sphingolipid Analysis
by LC-MS/MS
For the quantification of sphingolipids, cell pellets in methanol
were spiked with an internal standard solution (500 ng/ml
C17-Cer, 500 ng/ml Sph-d7, 500 ng/ml S1P-d7, and 500 ng/ml
Saph-d7; Avanti Polar Lipids, Alabaster, USA). Afterwards, lipid
extraction was performed twice using 35 µl of 1M HCl, 480 µl
of a salt-solution (0.74% KCl, 0.04% CaCl2, 0.034% MgCl2) and
600µl of chloroform. Thereafter, the aqueous layer was collected,
evaporated under a nitrogen stream and reconstituted in 100 µl
methanol for the injection into the LC-MS/MS system.
For the chromatographic separation a Luna C18 column
(Phenomenex, Aschaffenburg, Germany) was used. The two
mobile phases (A) water:formic acid (100:0.1, v/v) and (B)
acetonitrile: tetrahydrofuran:formic acid (50:50:0.1, v/v/v) were
used with a flow rate of 0.3 ml/min. Ten microliter of each
sample was injected into the system and the overall runtime was
16min using the following gradient: 60% of (A)/40% of (B) for
0.6min following a linear change within 3.9min to 0% (A)/100%
(B) and held for 6.5min. A second linear gradient was applied
within 0.5min to 60% (A)/40% (B) and held for 4.5min. MS/MS
analyses were performed on an API4000 triple quadrupole
system equipped with a TurboIonspray source (Electrospray
Ionization; Applied Biosystems, Darmstadt, Germany) operated
in positive mode. Two m/z transitions with a dwell time of
50ms were recorded: for quantification (380.2→ 264.2) and for
qualification (380.2 → 82.1), to exclude false positive results.
For analysis the Analyst Software 1.5 (Applied Biosystems,
Darmstadt, Germany) was used. Linearity of the calibration curve
was proven from 0.05 to 250 ng/ml. The coefficient of correlation
was at least 0.99. Variations in preciseness were less than 15% over
the range of calibration.
Quantitative Real-Time PCR
Total RNA of pelleted cells was extracted using the peqGOLD
Total RNA Kit (peqlab, Erlangen, Germany) as recommended
by the manufacturer. RNA concentration was measured
using the Nano-Drop 1000 (Thermo Scientific) analyzer and
was adjusted to 1 µg/µl for first-strand cDNA synthesis
using the high-capacity cDNA reverse transcription kit (Life
Technologies, Carlsbad, CA). TaqMan R© gene expression
assays (Life Technologies) were applied for Sphk1/2 and
for the housekeeping genes CsnK2a2 and Fbxo38, which were
purchased from Primer design (Southampton, United Kingdom).
The Precision FAST Mastermix (Primer Design) was used and
quantitative real-time PCR was run at 95◦C for 2min and 40
times at 95◦C for 5 s, 60◦C for 20 s (7500 Fast Real-Time PCR
System, Applied Biosystems). Data was evaluated using the mean
of the two housekeeping genes as a reference.
Statistics
The software GraphPad Prism 5.0 (La Jolla, CA) was used to
enter data, display graphs, and perform statistics by 1 way or
2 way ANOVA with Bonferroni posttest or paired Student’s t-
test. Data are represented as means ± SD and significant values
are symbolized as asterisks (∗/∗∗/∗∗∗) and hash keys (#, ##, ###),
which represent P-values of ≤0.05/≤0.01/≤0.001.
RESULTS
Activation-Induced Cell Death upon LPS
Stimulation
Bone marrow-derived DCs were stimulated with LPS over
72 h and secretion of a variety of cytokines was determined
(Figure 1A). High amounts of IL-6 and IL-10 were continuously
secreted into the medium, whereas IL-12 and IL-23 reached
a peak secretion 8 h after stimulation. Cell staining revealed
that cells undergo proliferation within the first 24 h upon
inflammatory stimulation (Figure 1B) Moreover, in this early
activation period cells exert a higher metabolic activity
(Figure 1C). After 24 h of stimulation, cell count declined.
However, strikingly, stimulated cells die faster than normal
cells. Annexin V/7-AAD staining revealed a higher frequency of
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FIGURE 1 | Function and survival of TLR4 stimulated DCs. GM-CSF differentiated cells have been stimulated with LPS for 0–72 h, (A) Quantification of cytokines
in the supernatant of stimulated cells over time, (B) Trypan Blue staining of unstimulated and LPS-stimulated cells over time, (C) XTT-test for metabolic activity in
unstimulated and 8 h LPS-stimulated cells, (D) FACS Annexin V and 7-AAD staining for apoptotic cells after 48 and 72 h of LPS-stimulation and in unstimulated cells,
(E) Western Blot analysis for ß-actin (38 kDa) and cleaved caspase 3 (17 kDa) after 6, 24, and 48 h of LPS-stimulation as well as in unstimulated cells and
staurosporin-treated cells as control. Time points of one group have been assembled on the same blot. Data represent mean ± SD, n ≥ 4 for each group, measured
in duplicates for (A–C); *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
apoptotic cells after LPS stimulation at late time points compared
to control cells (Figure 1D). Whereas, half of the resting cells
were still alive, 90% of activated DCs underwent apoptosis at
the end of the cultivation. Indicating the apoptotic pathway,
caspase 3 was highly activated 48 h after LPS stimulation in
comparison to unstimulated cells (Figure 1E). Notably, in TLR4-
stimulated cells, activation of caspase 3 was down regulated
during the initial 24 h of the hyper-activation phase compared
to baseline levels, whereas protein levels did not change in
untreated cells.
The Sphk1-S1P Axis Controls Activation
Induced Cell Death (AICD)
Since it is well-accepted, that S1P is an anti-apoptotic factor,
we examined dendritic cell survival and function in the absence
of the S1P-generating enzyme Sphk1. Interestingly, upon LPS
stimulation, Sphk1-deficient BM-DCs do not undergo hyper-
activation in the first 24 h and die faster, leaving alive only
one third of the cells after 72 h (Figure 2A). Basal S1P levels
were not significantly different between non-stimulated wild type
and Sphk1-knockout cells. However, early after stimulation, S1P
levels were significantly reduced in knockout cells vs. wild type
cells (Figure 2B). Indeed, S1P levels tend to increase in wild
type cells during the hyper-activation period whereas they rather
decrease in Sphk1-deficient cells. From 2 h after stimulation, S1P
level start to drop massively in both cell types. In accordance
with this finding, sphingosine levels were increased early after
stimulation in Sphk1-deficient cells (Figure 2C). Further analysis
of downstream lipids revealed a decrease of the ceramide
24/ceramide 18 (Cer24/Cer18) quotient indicating a higher
proliferative activity in wild type cells than in knockout cells
(Figure 2D). Furthermore, more apoptotic cells were determined
in Sphk1-deficient cells compared to wild type cells after TLR4
stimulation (Figure 2E).
Analysis of interleukins revealed a decrease of IL-23, IL-10,
and IL-6 level in an early phase after stimulation in Sphk1-
deficient cells (Figures 3A–C). In line with a reduced IL-23
and IL-6 secretion, also early expression of STAT3 was low
in cells lacking Sphk1, as opposed to increased mRNA levels
in LPS stimulated wild type DCs (Figure 3D). Interestingly,
Sphk1-deletion also affected BM-DC expansion during the
GM-CSF differentiation phase (Figure 3E). Treatment with
FTYP reduced cell growth significantly compared to wild
type cells. Also, in the latter cells LPS stimulation after the
differentiation phase resulted in a reduction of IL-23 secretion
by 50% (Figure 3F).
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FIGURE 2 | Survival of sphingosine kinase 1 knockout BM-derived DCs. GM-CSF-differentiated wild type and Sphk1-deficient cells have been stimulated with
LPS for 0–72 h (A) Trypan Blue staining of LPS-stimulated cells over time, (B) LCMS/MS based determination of absolute intracellular sphingosine 1 phosphate level
in wild type and Sphk1 deficient cells stimulated with LPS over time, (C,D) LC-MS/MS based determination of intracellular sphingosine, ceramide 24, and ceramide
18 levels in wild type and SphK1-deficient cells following 8 h of LPS stimulation, (E) FACS analysis of 7-AAD stained wild type and Sphk1-deficient cells upon 20 h of
LPS stimulation and in unstimulated control cells. Data represent mean ± SD, n ≥ 4 for each group; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
Regulation of Sphk1 Levels in Activated
DCs
Expression levels of Sphk1 slightly increased during early
stimulation in immune cells, however, levels rose massively by
about 70-fold in late DCs (Figure 4A). Notably, this massive
switch on of expression was not translated into protein levels,
which were rather decreased after 72 h compared to those after
48 h of LPS-stimulation (Figure 4B).
Since a compensatory regulation of Sphk1 and Sphk2 was
proposed, expression of both kinases was assessed on mRNA
level. During the early peak of Sphk1 expression at 4 h, the
Sphk2 level tended to drop at the same time (Figure 4C),
however no significant downregulation of Sphk2 mRNA was
found during the massive upregulation of Sphk1 mRNA in late
DCs. Interestingly, in Sphk1-deficient cells the same early drop
in Sphk2 mRNA concentration was found (Figure 4D) although
no Sphk1 is expressed in those cells (data not shown). Absolute
expression levels of both enzymes where not different under
basal condition in wild type cells (Figure 4E). While Sphk1
was massively upregulated under stimulation, Sphk2 showed no
change in expression levels.
DISCUSSION
Professional antigen presenting cells like DCs are pivotal in the
recognition of foreign bacterial and viral components and the
subsequent initiation of innate as well as of adaptive immune
responses providing differentiation and activation of T cell
subsets. Changes in the function and developmental status of
DCs are induced by inflammatory stimuli like cytokines and
bacterial products or by the cross-linking of surface molecules
(Winzler et al., 1997). In this study we showed that after reception
of such a signal, namely LPS, DCs accomplish maturation
by undergoing hyper-activation and proliferation within the
first 24 h. Notably, compared to immature DCs, the caspase 3
associated apoptotic pathway was diminished within this phase
allowing DCs to proliferate.
DCs have relatively short half-lives, nevertheless, during this
time, they are able to achieve successful antigen presentation
to T cells (Nopora and Brocker, 2002). Immature DCs of the
spleen are replaced within 3–4 days (Kamath et al., 2000)
suggesting a short DC lifespan regulated by programmed
apoptotic cell death. Granucci et al. described a regulation
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FIGURE 3 | Role of the Sphk1-S1P receptor module for function and expansion of DCs. (A–D) GM-CSF-differentiated wild type and Sphk1-deficient cells
have been stimulated with LPS for 0–72 h. (A–C) Quantification of cytokines in supernatants of stimulated wild type and Sphk1-deficient cells over time, (D)
Determination of STAT3 mRNA level by quantitative real time PCR in wild type and Sphk1-deficient cells after 8 h of LPS stimulation and in unstimulated cells, (E) bone
marrow cells from wild type and Sphk1-deficient mice have been differentiated with GM-CSF in the absence or presence of FTYP for 7 days and cell expansion has
been monitored by cell count. (F) IL-23 secretion upon 20 h of LPS stimulation in GM-CSF differentiated wild type cells and GM-CSF + FTYP differentiated
Sphk1-deficient cells. Data represent mean ± SD, n ≥ 4 for each group, measured in duplicates; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ##p ≤ 0.01.
of modulators of life cycle and apoptosis accompanying DC
activation (Granucci et al., 2001a,b). In our study, shortly
after hyper-activation phase, DCs underwent a rapid caspase
3 mediated apoptosis pathway in which the majority of the
cells were dead after 3 days while more than half of the
immature cells were still alive under the same conditions.
Hence, LPS-stimulated DCs undergo activation-induced cell
death (AICD). The death of activated DCs may be an important
contributor to the resolution of immune responses and to prevent
the development of autoimmunity (Chen and Wang, 2010).
Autoimmunity induced by DCs might be caused by increased
DC activity, thus, apoptosis of DCs, upon completion of their
task of antigen presentation, appears to serve as a negative
immunoregulatory mechanism that may be crucial in controlling
the magnitude of immune reactions against a given antigen
(Hildeman et al., 2007; Stranges et al., 2007). Supporting this
hypothesis, in our study LPS-activated DCs underwent faster
apoptosis compared to their non-stimulated mates. In parallel
to AICD of DCs we found S1P levels are tightly regulated
indicating an association between sphingolipid homeostasis and
cell survival.
Dysregulation of S1P concentrations are characteristic for
an increasing number of diseases with disturbed immune
modulation, especially autoimmune diseases (Bandhuvula
and Saba, 2007; Brinkmann et al., 2010; Lai et al., 2011).
Hence, it is of great importance to study the influence of
S1P metabolism in association with survival and function
of DCs.
As soon as S1P levels started to rise, DCs became active.
The cell proliferation and survival seemed to follow intracellular
S1P balances, since shortly after S1P concentrations were
dropping, cells underwent apoptosis and survival started to
decline. Strengthening this hypothesis, we found that Sphk1-
deficient cells did not undergo hyper-activation in congruence
with their S1P levels that did rather decrease than increase
right after stimulation. As stated by Hartmann et al., also
ceramides and especially ceramide chain length is decisive for
cell fate (Hartmann et al., 2013). While long chain ceramides are
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FIGURE 4 | Involvement of sphingosine kinases 1 and -2 in DC activation. GM-CSF differentiated wild type and Sphk1-deficient cells have been stimulated with
LPS for 0–72 h. (A,C,D) Determination of Sphk2 and Sphk1 mRNA level by quantitative real time PCR in wild type and Sphk1-deficient cells after LPS stimulation over
time normalized to level of unstimulated cells which was set to 1 at every time point (dotted line). (B) Western Blot analysis of Sphk1 (51 kDa) and ß-actin (38 kDa)
protein levels upon 48 and 72 h LPS stimulation and in unstimulated wild type cells. (E) Determination of absolute Sphk1 and Sphk2 mRNA level normalized to
housekeeping genes (set to 1) by quantitative real time PCR in wild type and Sphk1 deficient cells upon 72 h of LPS stimulation. Data represent mean ± SD, n ≥ 5 for
each group, measured in duplicates for (A–E); *p ≤ 0.05, ***p ≤ 0.001.
proliferative, shorter ceramides are pro-apoptotic. The C24/C18
ratio describes the proliferative activity of the cells and was clearly
reduced in Sphk1-deficient DCs. Accordingly, more apoptotic
cells were found in Sphk1-deficient cells indicating that lower S1P
levels decrease the activation responsiveness of DCs. Schwalm
et al. and others showed that upon induction of Sphk2-deficiency,
Sphk1 mRNA levels are upregulated in a compensatory manner
and thus proliferative activity of e.g., renal mesangial cells or
cancer cells is increasing (Liang et al., 2013; Schwalm et al.,
2015). Vice versa however, in our bone marrow derived DCs,
no significant compensatory regulation of Sphk2 mRNA was
observed neither in Sphk1-deficient cells nor in the late apoptotic
wild type cells where Sphk1 mRNA was massively accumulating.
This might suggest that Sphk1-mediated S1P production is the
key player in dendritic cell fate. Liang et al. and Lee et al.
linked the proliferative activity of Sphk2-deficiency and S1PR1
overexpression to persistent STAT3 activation in tumor cells (Lee
et al., 2011; Liang et al., 2013). Interestingly, in Sphk1-deficient
DCs, activation of STAT3 expression was missing upon LPS-
stimulation while in wild type cells levels started to rise very early
after DC activation. Also, the secretion of the STAT3-targeting
IL-23 was reduced in Sphk1-deficient cells especially during the
missing early phase of DC hyper-activation. This reduction of IL-
23 secretion of Sphk1 knockout cells suggests moreover, that the
ability to induce a Th17 response could be suppressed. Indeed
it was shown that Sphk1 knockout mice have fewer Th17 cells
reducing TNFα induced inflammation (Baker et al., 2010).While,
of the two additional cytokines known to be induced and at
least partially signaling through STAT3, the more systemically
functioning IL-6 was initially reduced but remained nearly
unaltered in summary, IL-10 was significantly dampened, which
may have an influence of subsequent Th1 response. Indeed, it was
found that INFγ production by T lymphocytes was reduced upon
Sphk1 inhibition indicating a suppression of the Th1 polarization
(Jung et al., 2007).
Confirming our in vitro results showing a reduced DC
activation, survival, and a possible reduced T-cell response
provoked by a decrease in cytokine secretion in Sphk1-deficient
cells, a reduced inflammatory response was shown in several
recent in vivo studies using Sphk1 mice. In a mouse model of
bacterial pathogen infection a reduced immune cell infiltration
was found in Sphk1 deficient mice due to reduced S1P levels
(Yu et al., 2016). Similarly, a reduced host defense against
fungal pathogens was elucidated in Sphk1 knockout mice
(Farnoud et al., 2015). In a model of allergic asthma it was
shown that Sphk1 inhibition with a specific inhibitor decreased
pulmonary inflammation (Price et al., 2013). Kawamori et al.
showed that Sphk1 knockout mice were less prone to DSS/AOM
induced colitis and associated colon cancerogenesis (Kawamori
et al., 2009), whereas clinical data demonstrated that Sphk1 is
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overexpressed in colorectal tumors (Liang et al., 2013). Beach and
colleagues showed a significant reduction of tumor growth and
metastasis in an ovarian cancer model in Sphk1 knockout mice
(Beach et al., 2015). Thus, our in vitro data in DCs may provide a
molecular explanation of the prominent role of Sphk1 in immune
response and even cancerogenesis.
Reduced Sphk1-S1P signaling also decreased dendritic cell
growth during expansion phase as administration of FTYP to
Sphk1-deficient cells diminished cell growth and IL-23 secretion
compared to wild type cells. Hence, the Sphk1-S1P axis seems
to be decisive for the distinct processes during the life circle
of DCs, i.e., expansion, activation, and apoptosis. At the same
time Sphk1 expression is tightly regulated in activated DCs. It
was shown before, that LPS-stimulation of splenocytes increases
the expression of Sphk1 by about tenfold within the first 2 h
with a sharp decline thereafter (Schroeder et al., 2011). In early
bone marrow-derived DCs a slight peak of Sphk1 mRNA was
detected as well, but more interestingly, we determined a massive
rise in Sphk1 mRNA in late apoptotic DCs. This upregulation
might be a compensatory mechanism resulting from the loss
of intracellular S1P levels, thus it seems to represent a rescue
mechanism to avoid the apoptotic machinery. It might also be
a reaction to the actual loss of Sphk1 protein in late DCs. In
contrast, Sphk2 mRNA regulation over time appeared to be
uncoupled from cell survival regulation by Sphk1 and S1P. As
a consequence of our new observations it is of great interest
to resolve the question how intracellular S1P levels are reduced
over time. Possible mechanisms include the dephosphorylation
to sphingosine, irreversible degradation e.g., by S1P lyase or
export out of the cell. S1P transport has been ascribed to different
ABC-transporters and spinster (SPNS2) in several cell types
(Kobayashi et al., 2009; Nieuwenhuis et al., 2009; Hisano et al.,
2012; Liu et al., 2012). However, it is still incompletely understood
which transporters are expressed in bone marrow derived DCs
and how much these plasma membrane transporters contribute
to intracellular amphiphilic S1P regulation in deep, double lipid
layer-separated compartments.
The key finding of this investigation is the closely intertwined
regulatory relationship of basic cellular sphingolipid metabolism
with highly specialized function of bone marrow-derived DCs.
The most significant observation and conclusion that may
be drawn is that potentially (i) pro-survival S1P supported
initiation of an inflammatory reaction within the first 24 h
whereas (ii) at later time points (48–72 h) a dangerous
survival of continuously pro-inflammatory DCs was prevented
by sphingolipid-related cell death. The latter finding of a
connection between AICD and sphingolipid metabolism in
DCs has not been shown before and might be relevant for
a better understanding of the molecular mechanisms that
regulate inflammatory responses, autoimmunity, and anti-cancer
immunity.
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